Sanofi inks marketing pact with Emcure for cancer drugs

Tags: Companies
Drug firm Sanofi has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India.

As per the agreement, Sanofi will continue to own its oncology range comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec, while Emcure will market and distribute these brands through its specialty unit, Sanofi India said in a filing to the BSE.

"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," Sanofi Vice-President-South Asia and Sanofi India Managing Director Shailesh Ayyangar said.

Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing oncology business, he added.

Emcure Pharmaceuticals Managing Director Satish Mehta said: "We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions."

Sanofi India Ltd shares were trading at Rs 2,886 a piece on the BSE in afternoon trade, up 0.27% from its previous close.

EDITORIAL OF THE DAY

  • The rights of terrorists are not more sacrosanct than the men fighting them

    In the light of the current goings on, there are relevant questions to ask.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

Disequilibrium : THE UGLY AND INCONVENIENT TRUTH

Same song, different verse. The time for polemics over how ...

Susan Visvanathan

What cambodia wants to hide

MP Joseph in his book My Driver Tulong, (Partridge ...

Zehra Naqvi

Interconnectedness of every life form

Human hubris makes us imagine ourselves as masters of the ...